Pfizer (PFE) Financials

$25.31 -0.02 (-0.08%)

Closing price 05/15/2026 03:59 PM Eastern

Extended Trading

$25.34 +0.03 (+0.12%)

As of 05/15/2026 08:00 PM Eastern

Annual Income Statements for Pfizer

This table shows Pfizer's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	6,960	7,215	21,308	11,153	16,026	9,159	21,979	31,372	2,119	8,031	7,771
Consolidated Net Income / (Loss)	6,986	7,246	21,355	11,188	16,056	9,195	22,025	31,407	2,158	8,062	7,812
Net Income / (Loss) Continuing Operations	6,975	7,229	21,353	3,861	10,738	6,666	22,459	31,401	2,172	8,051	7,787
Total Pre-Tax Income	8,965	8,351	12,305	3,594	11,321	7,036	24,311	34,729	1,058	8,023	7,520
Total Operating Income	11,824	12,145	13,722	5,672	6,710	8,250	19,433	35,789	1,279	12,411	14,244
Total Gross Profit	39,203	40,502	41,318	31,838	32,851	33,167	50,467	66,831	34,599	45,776	46,512
Total Revenue	48,851	52,824	52,546	40,825	40,905	41,651	81,288	101,175	59,553	63,627	62,579
Operating Revenue	48,851	52,824	52,546	40,825	40,905	41,651	81,288	101,175	59,553	63,627	62,579
Total Cost of Revenue	9,648	12,322	11,228	8,987	8,054	8,484	30,821	34,344	24,954	17,851	16,067
Operating Cost of Revenue	9,648	12,322	11,228	8,987	8,054	8,484	30,821	34,344	24,954	17,851	16,067
Total Operating Expenses	27,379	28,357	27,596	26,166	26,141	24,917	31,034	31,042	33,320	33,365	32,268
Selling, General & Admin Expense	14,809	14,844	14,804	12,612	12,726	11,597	12,703	13,677	14,771	14,730	13,794
Research & Development Expense	7,690	7,892	7,683	7,760	8,385	9,393	13,829	12,381	10,873	10,930	12,050
Amortization Expense	3,728	4,056	4,758	4,736	4,429	3,348	3,700	3,609	4,733	5,286	4,874
Restructuring Charge	1,152	1,565	351	1,058	601	579	802	1,375	2,943	2,419	1,550
Total Other Income / (Expense), net	-2,860	-3,794	-1,416	-2,077	4,610	-1,213	4,878	-1,062	-222	-4,388	-6,724
Other Income / (Expense), net	-2,860	-3,794	-1,416	-2,077	-3,497	-1,213	4,878	-1,062	-222	-4,388	-6,724
Income Tax Expense	1,990	1,123	-9,049	-266	583	370	1,852	3,328	-1,115	-28	-266
Net Income / (Loss) Discontinued Operations	11	17	2.00	7,328	5,318	2,529	-434	6.00	-15	11	25
Net Income / (Loss) Attributable to Noncontrolling Interest	26	31	47	36	29	36	45	35	39	31	41
Basic Earnings per Share	$1.13	$1.18	$3.57	$1.90	$2.88	$1.65	$3.92	$5.59	$0.38	$1.42	$1.37
Weighted Average Basic Shares Outstanding	6.18B	6.09B	5.97B	5.87B	5.57B	5.56B	5.60B	5.61B	5.64B	5.66B	5.68B
Diluted Earnings per Share	$1.11	$1.17	$3.52	$1.87	$2.82	$1.63	$3.85	$5.47	$0.37	$1.41	$1.36
Weighted Average Diluted Shares Outstanding	6.26B	6.16B	6.06B	5.98B	5.68B	5.63B	5.71B	5.73B	5.71B	5.70B	5.71B
Weighted Average Basic & Diluted Shares Outstanding	6.18B	6.11B	5.97B	5.87B	5.55B	5.58B	5.62B	5.62B	5.65B	5.67B	5.69B
Cash Dividends to Common per Share	$1.12	$1.22	-	$1.38	$1.46	$1.53	$1.57	$1.61	$1.65	$1.69	$1.72

This table shows Pfizer's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	10/1/2023	12/31/2023	3/31/2024	6/30/2024	9/29/2024	12/31/2024	3/30/2025	6/29/2025	9/28/2025	12/31/2025	3/29/2026
Net Income / (Loss) Attributable to Common Shareholders	-2,382	-3,369	3,115	41	4,465	410	2,967	2,910	3,541	-1,647	2,687
Consolidated Net Income / (Loss)	-2,376	-3,360	3,123	48	4,473	418	2,973	2,928	3,550	-1,639	2,696
Net Income / (Loss) Continuing Operations	-2,388	-3,335	3,128	31	4,481	411	2,973	2,903	3,550	-1,639	2,709
Total Pre-Tax Income	-3,352	-4,129	3,421	-103	4,715	-10	2,785	3,044	3,334	-1,643	3,170
Total Operating Income	-3,171	-4,288	4,102	1,003	4,959	2,347	3,738	3,783	3,851	2,872	4,032
Total Gross Profit	4,222	7,007	11,500	9,983	12,439	11,854	10,870	10,875	12,482	12,285	10,903
Total Revenue	13,491	14,569	14,879	13,283	17,702	17,763	13,715	14,653	16,654	17,557	14,451
Operating Revenue	13,491	14,569	14,879	13,283	17,702	17,763	13,715	14,653	16,654	17,557	14,451
Total Cost of Revenue	9,269	7,562	3,379	3,300	5,263	5,909	2,845	3,778	4,172	5,272	3,548
Operating Cost of Revenue	9,269	7,562	3,379	3,300	5,263	5,909	2,845	3,778	4,172	5,272	3,548
Total Operating Expenses	7,393	11,295	7,398	8,980	7,480	9,507	7,132	7,092	8,631	9,413	6,871
Selling, General & Admin Expense	3,281	4,575	3,495	3,717	3,244	4,274	3,031	3,415	3,186	4,162	2,961
Research & Development Expense	2,778	2,888	2,493	2,702	2,611	3,124	2,212	2,484	3,936	3,418	2,627
Amortization Expense	1,179	1,267	1,308	1,307	1,312	1,359	1,211	1,211	1,223	1,229	1,183
Restructuring Charge	155	2,565	102	1,254	313	750	678	-18	286	604	100
Total Other Income / (Expense), net	-181	159	-680	-1,107	-243	-2,358	-953	-739	-517	-4,515	-861
Other Income / (Expense), net	-181	159	-680	-1,107	-243	-2,358	-953	-739	-517	-4,515	-861
Income Tax Expense	-964	-795	293	-134	234	-421	-189	141	-216	-2.00	461
Net Income / (Loss) Discontinued Operations	12	-26	-5.00	17	-8.00	7.00	0.00	25	0.00	-	-13
Net Income / (Loss) Attributable to Noncontrolling Interest	6.00	9.00	8.00	7.00	8.00	8.00	6.00	18	9.00	8.00	8.00
Basic Earnings per Share	($0.42)	($0.59)	$0.55	$0.01	$0.79	$0.07	$0.52	$0.51	$0.62	($0.28)	$0.47
Weighted Average Basic Shares Outstanding	5.65B	5.64B	5.66B	5.67B	5.67B	5.66B	5.68B	5.69B	5.69B	5.68B	5.69B
Diluted Earnings per Share	($0.42)	($0.59)	$0.55	$0.01	$0.78	$0.07	$0.52	$0.51	$0.62	($0.29)	$0.47
Weighted Average Diluted Shares Outstanding	5.65B	5.71B	5.70B	5.70B	5.71B	5.70B	5.71B	5.71B	5.71B	5.71B	5.73B
Weighted Average Basic & Diluted Shares Outstanding	5.65B	5.65B	5.67B	5.67B	5.67B	5.67B	5.69B	5.69B	5.69B	5.69B	5.70B
Cash Dividends to Common per Share	$0.00	-	$0.00	$0.84	-	-	$0.00	$0.86	-	-	$0.00

This table details how cash moves in and out of Pfizer's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	-5,274	-1,042	-1,235	-89	125	475	159	-1,515	2,448	-1,810	91
Net Cash From Operating Activities	14,688	16,192	16,802	15,827	12,588	14,403	32,580	29,267	8,700	12,744	11,704
Net Cash From Continuing Operating Activities	13,883	16,192	16,800	8,875	7,015	10,540	32,922	29,267	8,701	12,743	11,705
Net Income / (Loss) Continuing Operations	6,986	7,246	21,355	3,860	10,738	6,666	22,459	31,401	2,172	8,051	7,787
Consolidated Net Income / (Loss)	6,986	7,246	21,355	11,188	16,056	9,195	22,025	31,407	2,158	8,062	7,812
Net Income / (Loss) Discontinued Operations	-	-	-	7,328	5,318	2,529	-434	6.00	-15	11	25
Depreciation Expense	5,157	5,757	6,269	6,150	5,755	4,681	5,191	5,064	6,290	7,013	6,592
Non-Cash Adjustments To Reconcile Net Income	1,019	3,091	912	1,402	-5,813	1,077	-3,238	2,205	2,411	2,847	2,680
Changes in Operating Assets and Liabilities, net	721	98	-11,736	-2,538	-3,664	-1,882	8,511	-9,403	-2,172	-5,168	-5,354
Net Cash From Investing Activities	-2,980	-7,791	-4,740	4,525	-3,945	-4,271	-22,546	-15,783	-32,278	2,652	-1,351
Net Cash From Continuing Investing Activities	-8,748	-7,791	-4,740	4,584	-3,825	-4,162	-22,534	-15,783	-32,277	2,654	-1,351
Purchase of Property, Plant & Equipment	-1,397	-1,823	-1,956	-1,984	-2,046	-2,226	-2,711	-3,236	-3,907	-2,909	-2,629
Acquisitions	-16,565	-18,544	-1,261	-152	-10,861	0.00	0.00	-22,997	-43,430	0.00	-6,927
Purchase of Investments	-38,123	-23,968	-18,133	-17,391	-7,036	-14,402	-39,525	-38,297	-31,178	-10,313	-14,650
Divestitures	-	-	-	-	-	-	-	0.00	0.00	7,040	6,311
Sale and/or Maturity of Investments	46,993	36,464	15,939	23,825	16,340	12,730	20,008	48,939	41,243	8,834	19,054
Other Investing Activities, net	344	80	671	287	-223	-265	-305	-192	4,995	2.00	-2,510
Net Cash From Financing Activities	-10,409	-9,228	-13,350	-20,441	-8,485	-9,649	-9,816	-14,834	26,066	-17,140	-10,304
Net Cash From Continuing Financing Activities	-10,409	-9,228	-13,349	-20,441	-8,485	-21,640	-9,816	-14,834	26,067	-17,140	-10,303
Repayment of Debt	-4,129	-13,318	-16,712	-10,208	-15,526	-26,644	-1,988	-7,520	-3,203	-13,945	-9,414
Payment of Dividends	-6,940	-7,317	-7,659	-7,978	-8,043	-8,440	-8,729	-8,983	-9,247	-9,512	-9,771
Issuance of Debt	5,557	15,388	15,160	8,685	23,948	13,445	901	3,669	38,517	6,317	8,882
Other Net Changes in Cash	-	-215	53	-	-32	-8.00	-59	-165	-40	-66	41
Cash Interest Paid	1,302	1,113	1,319	1,349	1,629	1,621	1,465	1,496	2,349	3,405	2,879
Cash Income Taxes Paid	2,383	2,521	2,489	3,655	3,664	3,153	7,427	7,867	3,147	3,605	4,688

This table details how cash moves in and out of Pfizer's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	10/1/2023	12/31/2023	3/31/2024	6/30/2024	9/29/2024	12/31/2024	3/30/2025	6/29/2025	9/28/2025	12/31/2025	3/29/2026
Net Change in Cash & Equivalents	535	-316	-2,137	343	29	-45	375	213	-301	-196	563
Net Cash From Operating Activities	3,456	5,240	1,090	-1,781	6,714	6,721	2,335	-582	4,603	5,348	2,615
Net Cash From Continuing Operating Activities	3,458	5,241	1,091	-1,781	6,713	6,720	2,334	-582	4,603	5,350	2,616
Net Income / (Loss) Continuing Operations	-2,388	-3,335	3,128	31	4,481	411	2,973	2,903	3,551	-1,640	2,709
Consolidated Net Income / (Loss)	-2,376	-3,360	3,123	48	4,473	418	2,973	2,928	3,551	-1,640	2,696
Net Income / (Loss) Discontinued Operations	12	-26	-5.00	17	-8.00	7.00	0.00	25	-	-	-13
Depreciation Expense	1,560	1,670	1,736	1,731	1,755	1,791	1,618	1,625	1,662	1,687	1,613
Non-Cash Adjustments To Reconcile Net Income	5,598	314	4.00	775	80	1,988	325	151	-1,509	3,713	38
Changes in Operating Assets and Liabilities, net	-1,312	6,592	-3,777	-4,318	397	2,530	-2,582	-5,261	899	1,590	-1,744
Net Cash From Investing Activities	888	-10,996	1,732	4,600	-2,057	-1,623	3,274	3,951	-2,430	-6,146	785
Net Cash From Continuing Investing Activities	890	-10,997	1,731	4,601	-2,058	-1,620	3,275	3,948	-2,428	-6,146	785
Purchase of Property, Plant & Equipment	-810	-1,044	-704	-637	-651	-917	-564	-618	-602	-845	-436
Purchase of Investments	-9,206	-874	-832	-530	-2,670	-6,281	-2,957	-3,214	-4,352	-4,127	-2,673
Divestitures	-	-	3,491	-	-	3,549	6,311	-	-	-	0.00
Sale and/or Maturity of Investments	10,556	34,312	-224	5,786	1,258	2,014	185	7,792	2,512	8,565	3,872
Other Investing Activities, net	350	14	0.00	-18	5.00	15	300	-12	14	-2,812	22
Net Cash From Financing Activities	-3,779	5,442	-4,931	-2,459	-4,636	-5,114	-5,227	-3,196	-2,477	596	-2,856
Net Cash From Continuing Financing Activities	-3,779	5,442	-4,931	-2,459	-4,636	-5,114	-5,227	-3,197	-2,476	597	-2,856
Repayment of Debt	-1,337	-21	-1,964	-5,587	-2,928	-3,466	-2,404	-3,922	-38	-3,050	-284
Payment of Dividends	-2,314	-2,315	-2,372	-2,380	-2,380	-2,380	-2,437	-2,445	-2,444	-2,445	-2,445
Issuance of Debt	-128	7,778	-595	5,508	672	732	-386	3,170	6.00	6,092	-127
Other Net Changes in Cash	-32	-1.00	-28	-18	9.00	-29	-7.00	41	2.00	5.00	19
Cash Interest Paid	399	1,098	448	1,103	313	1,541	427	1,085	341	1,026	355
Cash Income Taxes Paid	882	240	184	2,502	486	433	152	3,341	178	1,017	72

This table presents Pfizer's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	167,381	171,615	171,797	159,422	167,594	154,229	181,475	197,205	226,501	213,396	208,160
Total Current Assets	43,804	38,949	41,142	49,926	32,803	35,067	59,693	51,259	43,333	50,358	42,898
Cash & Equivalents	3,641	2,595	1,342	1,139	1,121	1,786	1,944	416	2,853	1,043	1,142
Short-Term Investments	19,649	15,255	18,650	17,694	8,525	10,437	29,125	22,316	9,837	19,434	12,454
Accounts Receivable	8,176	8,225	8,221	8,025	6,772	7,913	11,479	10,952	11,566	11,463	11,874
Inventories, net	7,513	6,783	7,578	7,508	7,068	8,020	9,059	8,981	10,189	10,851	10,654
Current Deferred & Refundable Income Taxes	2,662	3,041	3,050	3,374	2,736	3,264	4,266	3,577	3,978	3,314	3,967
Other Current Assets	2,154	2,249	2,289	2,461	2,357	3,646	3,820	5,017	4,911	4,253	2,808
Plant, Property, & Equipment, net	13,766	13,318	13,865	13,385	12,969	13,745	14,882	16,274	18,940	18,393	19,317
Total Noncurrent Assets	109,811	119,348	116,790	96,112	121,822	105,417	106,900	129,670	164,228	144,645	145,946
Long-Term Investments	15,999	7,116	7,015	2,767	20,147	20,262	21,526	15,069	15,368	2,228	1,621
Goodwill	48,242	54,449	55,952	53,411	48,202	49,556	49,208	51,375	67,783	68,527	71,264
Intangible Assets	40,356	52,648	48,741	35,211	33,936	28,337	25,146	43,370	64,900	55,411	53,731
Noncurrent Deferred & Refundable Income Taxes	1,794	1,812	1,855	1,924	1,911	2,383	3,341	6,693	3,706	8,662	9,699
Other Noncurrent Operating Assets	3,420	3,323	3,227	2,799	4,199	4,879	7,679	13,163	12,471	9,817	9,631
Total Liabilities & Shareholders' Equity	140,505	171,615	171,797	159,422	167,594	154,229	181,476	197,205	226,501	213,396	208,160
Total Liabilities	75,507	111,775	100,141	95,664	104,148	90,756	104,013	101,288	137,213	124,899	121,385
Total Current Liabilities	29,399	31,115	30,427	31,858	37,304	25,920	42,671	42,138	47,794	42,995	36,984
Short-Term Debt	10,159	10,688	9,953	8,831	16,195	2,703	2,241	2,945	10,350	6,946	3,154
Accounts Payable	3,620	4,536	4,656	4,674	3,887	4,283	5,578	6,809	6,710	5,633	5,240
Dividends Payable	1,852	1,944	2,029	2,047	2,104	2,162	2,249	2,303	2,372	2,437	2,445
Current Deferred & Payable Income Tax Liabilities	418	437	477	1,265	980	1,049	1,266	1,587	2,349	2,910	3,103
Current Employee Benefit Liabilities	2,359	2,487	2,196	2,397	2,390	3,049	3,332	3,407	2,776	3,838	3,610
Other Current Liabilities	10,990	11,023	11,115	10,753	9,334	11,561	24,939	22,568	20,537	19,720	19,432
Total Noncurrent Liabilities	46,108	80,660	69,714	63,806	66,844	64,836	61,342	59,149	89,418	81,904	84,399
Long-Term Debt	28,740	31,398	33,538	32,909	35,955	37,133	36,195	32,884	61,538	57,405	61,641
Noncurrent Deferred & Payable Income Tax Liabilities	3,992	34,753	22,597	18,437	17,778	15,623	11,680	10,835	9,174	8,234	5,992
Noncurrent Employee Benefit Liabilities	8,119	8,172	7,430	6,610	6,217	5,411	3,724	2,250	2,167	2,115	2,041
Other Noncurrent Operating Liabilities	5,257	6,337	6,149	5,850	6,894	6,669	9,743	13,180	16,539	14,150	14,725
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	64,998	59,840	71,656	63,758	63,447	63,473	77,462	95,916	89,288	88,497	86,775
Total Preferred & Common Equity	64,720	59,544	71,308	63,407	63,143	63,238	77,200	95,661	89,014	88,203	86,476
Total Common Equity	64,694	59,520	71,287	63,389	63,125	63,238	77,200	95,661	89,014	88,203	86,476
Common Stock	81,475	83,146	84,742	86,720	87,896	89,144	91,064	92,278	93,109	94,083	94,950
Retained Earnings	71,993	71,774	85,291	89,554	97,670	90,392	103,394	125,656	118,353	116,725	114,610
Treasury Stock	-79,252	-84,364	-89,425	-101,610	-110,801	-110,988	-111,361	-113,969	-114,487	-114,763	-115,015
Accumulated Other Comprehensive Income / (Loss)	-9,522	-11,036	-9,321	-11,275	-11,640	-5,310	-5,897	-8,304	-7,961	-7,842	-8,069
Noncontrolling Interest	278	296	348	351	303	235	262	256	274	294	299

This table presents Pfizer's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026
Period end date	7/2/2023	10/1/2023	12/31/2023	3/31/2024	6/30/2024	9/29/2024	12/31/2024	3/30/2025	6/29/2025	9/28/2025	3/29/2026
Total Assets	220,168	215,021	226,501	221,095	216,193	219,476	213,396	208,028	206,095	208,731	207,618
Total Current Assets	73,347	74,012	43,333	42,415	37,825	43,223	50,358	45,861	43,703	46,924	42,822
Cash & Equivalents	2,632	3,148	2,853	719	1,052	1,092	1,043	1,430	1,638	1,343	1,703
Short-Term Investments	42,153	41,033	9,837	11,209	6,048	8,860	19,434	15,887	11,611	13,641	11,372
Accounts Receivable	10,231	11,086	11,566	10,989	11,393	14,451	11,463	11,845	12,078	14,260	12,585
Inventories, net	10,310	10,204	10,189	10,892	11,447	11,721	10,851	10,852	11,669	11,468	10,667
Current Deferred & Refundable Income Taxes	3,194	3,917	3,978	4,233	3,694	3,243	3,314	2,900	4,016	3,855	3,588
Other Current Assets	4,828	4,624	4,911	4,372	4,190	3,855	4,253	2,947	2,690	2,358	2,908
Plant, Property, & Equipment, net	17,488	17,862	18,940	18,803	18,957	18,541	18,393	18,347	18,776	18,880	19,402
Total Noncurrent Assets	129,333	123,148	164,228	159,878	159,410	157,713	144,644	143,820	143,617	142,927	145,393
Long-Term Investments	15,066	14,239	15,368	11,613	11,148	10,762	2,227	2,013	2,120	2,137	1,626
Goodwill	51,572	51,527	67,783	69,297	68,445	68,570	68,527	68,444	68,997	69,101	71,409
Intangible Assets	41,406	40,224	64,900	62,829	61,240	59,986	55,411	53,976	52,702	51,324	52,559
Noncurrent Deferred & Refundable Income Taxes	8,261	8,350	3,706	4,942	7,867	7,909	8,662	9,542	10,343	11,048	9,965
Other Noncurrent Operating Assets	13,028	8,808	12,471	11,197	10,710	10,486	9,817	9,845	9,455	9,317	9,834
Total Liabilities & Shareholders' Equity	220,168	215,021	226,501	221,095	216,193	219,476	213,396	208,028	206,095	208,731	207,618
Total Liabilities	120,875	117,817	137,213	128,537	128,218	126,918	124,899	117,391	117,083	115,635	117,214
Total Current Liabilities	34,647	31,136	47,794	40,497	43,819	43,211	42,995	36,452	37,726	36,596	34,348
Short-Term Debt	3,985	2,548	10,350	8,232	11,944	9,699	6,946	4,470	4,295	4,303	3,890
Accounts Payable	6,081	5,338	6,710	5,591	5,106	5,314	5,633	5,240	5,166	5,024	4,506
Dividends Payable	2,315	0.00	2,372	0.00	2,380	0.00	2,437	0.00	2,445	0.00	0.00
Current Deferred & Payable Income Tax Liabilities	2,928	1,898	2,349	3,192	2,884	2,877	2,910	3,105	3,675	3,799	3,130
Current Employee Benefit Liabilities	1,972	2,372	2,776	2,192	2,566	3,383	3,838	2,607	2,447	3,036	2,715
Other Current Liabilities	16,079	16,776	20,537	18,788	16,410	19,917	19,720	20,016	18,575	19,509	20,108
Total Noncurrent Liabilities	86,227	86,680	89,418	88,039	84,400	83,707	81,904	80,939	79,357	79,039	82,866
Long-Term Debt	61,356	61,048	61,538	61,307	57,506	58,002	57,405	57,639	57,502	57,409	60,565
Noncurrent Deferred & Payable Income Tax Liabilities	9,284	9,224	9,174	9,534	8,759	8,063	8,234	7,982	5,794	5,868	6,117
Noncurrent Employee Benefit Liabilities	2,184	2,166	2,167	2,076	2,040	2,073	2,115	2,021	2,130	2,157	1,984
Other Noncurrent Operating Liabilities	13,403	14,242	16,539	15,122	16,095	15,569	14,150	13,297	13,931	13,605	14,200
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	99,293	97,204	89,288	92,558	87,975	92,558	88,497	90,637	89,012	93,096	90,404
Total Preferred & Common Equity	99,019	96,934	89,014	92,282	87,700	92,286	88,203	90,338	88,695	92,801	90,101
Total Common Equity	99,019	96,934	89,014	92,282	87,700	92,285	88,203	90,338	88,695	92,802	90,100
Common Stock	92,807	92,974	93,109	93,477	93,677	93,957	94,083	94,337	94,534	94,729	95,255
Retained Earnings	128,796	126,411	118,353	121,318	116,596	121,059	116,725	119,590	117,609	121,150	117,238
Treasury Stock	-114,482	-114,485	-114,487	-114,755	-114,757	-114,760	-114,763	-115,008	-115,010	-115,011	-115,190
Accumulated Other Comprehensive Income / (Loss)	-8,102	-7,966	-7,961	-7,758	-7,816	-7,971	-7,842	-8,581	-8,438	-8,066	-7,203
Noncontrolling Interest	274	270	274	276	275	272	294	299	317	295	303

This table displays calculated financial ratios and metrics derived from Pfizer's official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-1.52%	8.13%	-0.53%	-22.30%	0.20%	1.82%	95.16%	24.46%	-41.14%	6.84%	-1.65%
EBITDA Growth	-20.57%	-0.09%	31.65%	-47.53%	-7.97%	30.66%	151.77%	34.88%	-81.54%	104.66%	-6.15%
EBIT Growth	-26.76%	-6.84%	47.34%	-70.78%	-10.63%	119.02%	245.47%	42.84%	-96.96%	659.04%	-6.27%
NOPAT Growth	-6.81%	14.27%	126.50%	-74.41%	4.48%	22.81%	129.69%	80.25%	-91.88%	374.11%	18.42%
Net Income Growth	-23.80%	3.72%	194.71%	-47.61%	43.51%	-42.73%	139.53%	42.60%	-93.13%	273.59%	-3.10%
EPS Growth	-21.83%	5.41%	200.85%	-46.88%	50.80%	-42.20%	136.20%	42.08%	-93.24%	281.08%	-3.55%
Operating Cash Flow Growth	-14.02%	10.24%	3.77%	-5.80%	-20.47%	14.42%	126.20%	-10.17%	-70.27%	46.48%	-8.16%
Free Cash Flow Firm Growth	-242.66%	192.73%	-54.33%	54.30%	-34.91%	-36.47%	238.44%	-93.44%	-2,300.11%	141.96%	-44.52%
Invested Capital Growth	65.55%	-16.31%	15.43%	-13.36%	-6.97%	0.43%	-10.19%	46.83%	40.78%	-2.15%	4.69%
Revenue Q/Q Growth	1.94%	-0.79%	0.14%	-23.51%	1.71%	29.89%	18.02%	1.30%	-14.03%	7.16%	-0.33%
EBITDA Q/Q Growth	-12.76%	9.79%	1.09%	-51.52%	13.56%	260.78%	13.16%	4.20%	-55.61%	39.26%	-10.95%
EBIT Q/Q Growth	-19.40%	15.70%	1.45%	-73.92%	72.37%	583.98%	15.18%	4.26%	-89.85%	105.45%	-17.83%
NOPAT Q/Q Growth	0.37%	-1.43%	123.11%	-74.84%	26.28%	326.34%	12.83%	7.27%	-73.82%	139.28%	0.01%
Net Income Q/Q Growth	-16.75%	15.07%	116.89%	-53.09%	-1.22%	18.42%	13.00%	5.41%	-79.49%	88.19%	-20.84%
EPS Q/Q Growth	-16.54%	15.84%	117.28%	-52.78%	-1.74%	18.98%	12.90%	5.19%	-79.67%	88.00%	-20.93%
Operating Cash Flow Q/Q Growth	-4.56%	7.60%	6.65%	-12.93%	-7.15%	14.79%	0.90%	10.03%	-27.75%	13.15%	-10.50%
Free Cash Flow Firm Q/Q Growth	-7,467.04%	336.40%	-73.37%	13.74%	210.05%	77.99%	-34.91%	-88.99%	-247.07%	148.08%	-48.65%
Invested Capital Q/Q Growth	-1.38%	-32.77%	9.00%	-14.15%	-21.19%	-18.75%	-1.79%	17.66%	32.34%	-4.99%	0.81%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	80.25%	76.67%	78.63%	77.99%	80.31%	79.63%	62.08%	66.05%	58.10%	71.94%	74.33%
EBITDA Margin	28.91%	26.71%	35.35%	23.87%	21.92%	28.13%	36.29%	39.33%	12.34%	23.63%	22.55%
Operating Margin	24.20%	22.99%	26.11%	13.89%	16.40%	19.81%	23.91%	35.37%	2.15%	19.51%	22.76%
EBIT Margin	18.35%	15.81%	23.42%	8.81%	7.85%	16.90%	29.91%	34.32%	1.77%	12.61%	12.02%
Profit (Net Income) Margin	14.30%	13.72%	40.64%	27.40%	39.25%	22.08%	27.10%	31.04%	3.62%	12.67%	12.48%
Tax Burden Percent	77.93%	86.77%	173.55%	311.30%	141.82%	130.69%	90.60%	90.43%	203.97%	100.49%	103.88%
Interest Burden Percent	100.01%	100.00%	100.01%	99.97%	352.35%	99.99%	100.00%	100.01%	100.09%	100.00%	100.00%
Effective Tax Rate	22.20%	13.45%	-73.54%	-7.40%	5.15%	5.26%	7.62%	9.58%	-105.39%	-0.35%	-3.54%
Return on Invested Capital (ROIC)	12.29%	12.26%	28.30%	7.24%	8.44%	10.73%	25.92%	40.00%	2.27%	9.29%	10.87%
ROIC Less NNEP Spread (ROIC-NNEP)	-21.55%	-1.75%	14.95%	38.26%	90.65%	25.45%	-313.59%	56.45%	0.25%	-0.44%	-3.56%
Return on Net Nonoperating Assets (RNNOA)	-2.06%	-0.66%	4.18%	9.28%	16.80%	3.76%	5.34%	-3.77%	0.06%	-0.22%	-1.95%
Return on Equity (ROE)	10.23%	11.61%	32.48%	16.52%	25.24%	14.49%	31.26%	36.23%	2.33%	9.07%	8.91%
Cash Return on Invested Capital (CROIC)	-37.08%	30.03%	13.97%	21.56%	15.66%	10.30%	36.65%	2.06%	-31.60%	11.46%	6.28%
Operating Return on Assets (OROA)	5.35%	4.93%	7.17%	2.17%	1.97%	4.37%	14.48%	18.34%	0.50%	3.65%	3.57%
Return on Assets (ROA)	4.17%	4.28%	12.44%	6.76%	9.82%	5.71%	13.12%	16.59%	1.02%	3.67%	3.71%
Return on Common Equity (ROCE)	10.18%	11.55%	32.31%	16.43%	25.11%	14.43%	31.15%	36.12%	2.32%	9.04%	8.88%
Return on Equity Simple (ROE_SIMPLE)	10.79%	12.17%	29.95%	17.64%	25.43%	14.54%	28.53%	32.83%	2.42%	9.14%	0.00%
Net Operating Profit after Tax (NOPAT)	9,199	10,512	23,810	6,092	6,364	7,816	17,953	32,359	2,627	12,454	14,748
NOPAT Margin	18.83%	19.90%	45.31%	14.92%	15.56%	18.77%	22.09%	31.98%	4.41%	19.57%	23.57%
Net Nonoperating Expense Percent (NNEP)	33.84%	14.02%	13.35%	-31.02%	-82.21%	-14.72%	339.51%	-16.45%	2.02%	9.73%	14.43%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	24.56%	1.63%	8.15%	9.73%
Cost of Revenue to Revenue	19.75%	23.33%	21.37%	22.01%	19.69%	20.37%	37.92%	33.95%	41.90%	28.06%	25.67%
SG&A Expenses to Revenue	30.31%	28.10%	28.17%	30.89%	31.11%	27.84%	15.63%	13.52%	24.80%	23.15%	22.04%
R&D to Revenue	15.74%	14.94%	14.62%	19.01%	20.50%	22.55%	17.01%	12.24%	18.26%	17.18%	19.26%
Operating Expenses to Revenue	56.05%	53.68%	52.52%	64.09%	63.91%	59.82%	38.18%	30.68%	55.95%	52.44%	51.56%
Earnings before Interest and Taxes (EBIT)	8,964	8,351	12,304	3,595	3,213	7,037	24,311	34,727	1,057	8,023	7,520
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	14,121	14,108	18,573	9,745	8,968	11,718	29,502	39,791	7,347	15,036	14,112
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.18	2.43	2.31	3.15	2.82	2.76	3.81	2.67	1.69	1.68	1.61
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	103.26	278.47	0.00	0.00	0.00
Price to Revenue (P/Rev)	2.89	2.74	3.14	4.89	4.35	4.19	3.62	2.52	2.53	2.32	2.23
Price to Earnings (P/E)	20.26	20.06	7.73	17.88	11.09	19.06	13.37	8.13	71.12	18.42	17.92
Dividend Yield	4.90%	5.03%	4.63%	3.94%	4.48%	4.84%	2.98%	3.52%	6.14%	6.44%	7.02%
Earnings Yield	4.94%	4.99%	12.93%	5.59%	9.02%	5.25%	7.48%	12.30%	1.41%	5.43%	5.58%
Enterprise Value to Invested Capital (EV/IC)	1.51	2.08	2.01	2.82	2.76	2.50	4.27	2.63	1.44	1.43	1.36
Enterprise Value to Revenue (EV/Rev)	2.88	3.07	3.46	5.39	4.90	4.37	3.44	2.50	3.27	2.98	3.02
Enterprise Value to EBITDA (EV/EBITDA)	9.98	11.50	9.78	22.57	22.35	15.55	9.49	6.37	26.52	12.63	13.40
Enterprise Value to EBIT (EV/EBIT)	15.72	19.42	14.76	61.18	62.38	25.89	11.52	7.30	184.30	23.66	25.15
Enterprise Value to NOPAT (EV/NOPAT)	15.32	15.43	7.63	36.11	31.49	23.31	15.60	7.83	74.16	15.24	12.82
Enterprise Value to Operating Cash Flow (EV/OCF)	9.59	10.02	10.81	13.90	15.92	12.65	8.59	8.66	22.39	14.90	16.16
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	6.30	15.45	12.13	16.98	24.29	11.03	152.22	0.00	12.35	22.18
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.60	0.70	0.61	0.65	0.82	0.63	0.50	0.37	0.81	0.73	0.75
Long-Term Debt to Equity	0.44	0.52	0.47	0.52	0.57	0.59	0.47	0.34	0.69	0.65	0.71
Financial Leverage	0.10	0.37	0.28	0.24	0.19	0.15	-0.02	-0.07	0.25	0.51	0.55
Leverage Ratio	2.45	2.72	2.61	2.45	2.57	2.54	2.38	2.18	2.29	2.47	2.41
Compound Leverage Factor	2.45	2.72	2.61	2.45	9.06	2.54	2.38	2.18	2.29	2.47	2.41
Debt to Total Capital	37.44%	41.29%	37.77%	39.56%	45.11%	38.56%	33.16%	27.20%	44.60%	42.10%	42.75%
Short-Term Debt to Total Capital	9.78%	10.49%	8.64%	8.37%	14.01%	2.62%	1.93%	2.24%	6.42%	4.54%	2.08%
Long-Term Debt to Total Capital	27.66%	30.80%	29.13%	31.19%	31.10%	35.94%	31.23%	24.96%	38.18%	37.56%	40.67%
Preferred Equity to Total Capital	0.03%	0.02%	0.02%	0.02%	0.01%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.27%	0.29%	0.30%	0.33%	0.26%	0.23%	0.23%	0.19%	0.17%	0.19%	0.20%
Common Equity to Total Capital	62.27%	58.40%	61.91%	60.08%	54.61%	61.21%	66.61%	72.61%	55.23%	57.71%	57.05%
Debt to EBITDA	2.75	2.98	2.34	4.28	5.82	3.40	1.30	0.90	9.78	4.28	4.59
Net Debt to EBITDA	-0.03	1.21	0.89	2.07	2.49	0.63	-0.48	-0.05	5.97	2.77	3.51
Long-Term Debt to EBITDA	2.04	2.23	1.81	3.38	4.01	3.17	1.23	0.83	8.38	3.82	4.37
Debt to NOPAT	4.23	4.00	1.83	6.85	8.19	5.10	2.14	1.11	27.37	5.17	4.39
Net Debt to NOPAT	-0.04	1.63	0.69	3.31	3.51	0.94	-0.79	-0.06	16.69	3.34	3.36
Long-Term Debt to NOPAT	3.12	2.99	1.41	5.40	5.65	4.75	2.02	1.02	23.43	4.61	4.18
Altman Z-Score	2.29	1.89	2.30	2.50	2.12	2.47	3.50	3.55	1.65	1.94	1.91
Noncontrolling Interest Sharing Ratio	0.48%	0.50%	0.52%	0.55%	0.54%	0.44%	0.35%	0.30%	0.29%	0.32%	0.34%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.49	1.25	1.35	1.57	0.88	1.35	1.40	1.22	0.91	1.17	1.16
Quick Ratio	1.07	0.84	0.93	0.84	0.44	0.78	1.00	0.80	0.51	0.74	0.69
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-27,754	25,737	11,755	18,138	11,806	7,501	25,387	1,664	-36,619	15,366	8,526
Operating Cash Flow to CapEx	1,051.40%	888.21%	859.00%	797.73%	615.25%	647.04%	1,201.77%	904.42%	222.68%	438.09%	445.19%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.29	0.31	0.31	0.25	0.25	0.26	0.48	0.53	0.28	0.29	0.30
Accounts Receivable Turnover	5.89	6.44	6.39	5.03	5.53	5.67	8.38	9.02	5.29	5.53	5.36
Inventory Turnover	1.46	1.72	1.56	1.19	1.11	1.12	3.61	3.81	2.60	1.70	1.49
Fixed Asset Turnover	3.83	3.90	3.87	3.00	3.10	3.12	5.68	6.49	3.38	3.41	3.32
Accounts Payable Turnover	2.83	3.02	2.44	1.93	1.88	2.08	6.25	5.55	3.69	2.89	2.96
Days Sales Outstanding (DSO)	61.93	56.66	57.12	72.62	66.02	64.34	43.54	40.46	69.01	66.05	68.06
Days Inventory Outstanding (DIO)	249.24	211.74	233.42	306.35	330.29	324.56	101.13	95.86	140.20	215.10	244.27
Days Payable Outstanding (DPO)	129.20	120.80	149.41	189.47	193.99	175.75	58.39	65.82	98.87	126.19	123.50
Cash Conversion Cycle (CCC)	181.97	147.60	141.14	189.51	202.31	213.16	86.28	70.50	110.33	154.97	188.82
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	93,328	78,103	90,158	78,112	72,670	72,985	65,551	96,246	135,492	132,580	138,802
Invested Capital Turnover	0.65	0.62	0.62	0.49	0.54	0.57	1.17	1.25	0.51	0.47	0.46
Increase / (Decrease) in Invested Capital	36,953	-15,225	12,055	-12,046	-5,442	315	-7,434	30,695	39,246	-2,912	6,222
Enterprise Value (EV)	140,905	162,174	181,627	219,960	200,436	182,177	279,990	253,360	194,808	189,841	189,119
Market Capitalization	140,991	144,734	164,774	199,450	177,759	174,591	293,887	255,076	150,704	147,900	139,242
Book Value per Share	$10.48	$9.81	$11.96	$10.97	$11.41	$11.38	$13.75	$17.04	$15.76	$15.56	$15.21
Tangible Book Value per Share	($3.87)	($7.84)	($5.60)	($4.37)	($3.44)	($2.64)	$0.51	$0.16	($7.73)	($6.31)	($6.77)
Total Capital	103,897	101,926	115,147	105,498	115,597	103,309	115,898	131,745	161,176	152,848	151,570
Total Debt	38,899	42,086	43,491	41,740	52,150	39,836	38,436	35,829	71,888	64,351	64,795
Total Long-Term Debt	28,740	31,398	33,538	32,909	35,955	37,133	36,195	32,884	61,538	57,405	61,641
Net Debt	-390	17,120	16,484	20,140	22,357	7,351	-14,159	-1,972	43,830	41,647	49,578
Capital Expenditures (CapEx)	1,397	1,823	1,956	1,984	2,046	2,226	2,711	3,236	3,907	2,909	2,629
Debt-free, Cash-free Net Working Capital (DFCFNWC)	1,274	672	676	8,066	2,048	-373	-11,806	-10,666	-6,801	-6,168	-4,528
Debt-free Net Working Capital (DFNWC)	24,564	18,522	20,668	26,899	11,694	11,850	19,263	12,066	5,889	14,309	9,068
Net Working Capital (NWC)	14,405	7,834	10,715	18,068	-4,501	9,147	17,022	9,121	-4,461	7,363	5,914
Net Nonoperating Expense (NNE)	2,213	3,266	2,455	-5,096	-9,692	-1,379	-4,072	952	469	4,392	6,936
Net Nonoperating Obligations (NNO)	28,330	18,263	18,502	14,354	9,223	9,512	-11,911	330	46,204	44,083	52,027
Total Depreciation and Amortization (D&A)	5,157	5,757	6,269	6,150	5,755	4,681	5,191	5,064	6,290	7,013	6,592
Debt-free, Cash-free Net Working Capital to Revenue	2.61%	1.27%	1.29%	19.76%	5.01%	-0.90%	-14.52%	-10.54%	-11.42%	-9.69%	-7.24%
Debt-free Net Working Capital to Revenue	50.28%	35.06%	39.33%	65.89%	28.59%	28.45%	23.70%	11.93%	9.89%	22.49%	14.49%
Net Working Capital to Revenue	29.49%	14.83%	20.39%	44.26%	-11.00%	21.96%	20.94%	9.02%	-7.49%	11.57%	9.45%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$1.13	$1.18	$3.57	$1.90	$2.92	$1.73	$3.92	$5.59	$0.38	$1.42	$1.37
Adjusted Weighted Average Basic Shares Outstanding	6.18B	6.09B	5.97B	5.87B	5.57B	5.56B	5.60B	5.61B	5.64B	5.66B	5.68B
Adjusted Diluted Earnings per Share	$1.11	$1.17	$3.52	$1.87	$2.87	$1.71	$3.85	$5.47	$0.37	$1.41	$1.36
Adjusted Weighted Average Diluted Shares Outstanding	6.26B	6.16B	6.06B	5.98B	5.68B	5.63B	5.71B	5.73B	5.71B	5.70B	5.71B
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$2.92	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	6.18B	5.95B	5.95B	5.55B	5.55B	5.58B	5.62B	5.62B	5.65B	5.67B	5.69B
Normalized Net Operating Profit after Tax (NOPAT)	10,096	11,866	9,850	4,711	6,935	8,365	18,694	33,603	2,955	10,381	11,056
Normalized NOPAT Margin	20.67%	22.46%	18.75%	11.54%	16.95%	20.08%	23.00%	33.21%	4.96%	16.32%	17.67%
Pre Tax Income Margin	18.35%	15.81%	23.42%	8.80%	27.68%	16.89%	29.91%	34.33%	1.78%	12.61%	12.02%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	99.34%	100.98%	35.87%	71.31%	50.09%	91.79%	39.63%	28.60%	428.50%	117.99%	125.08%
Augmented Payout Ratio	187.52%	169.98%	59.28%	180.34%	105.31%	91.79%	39.63%	34.97%	428.50%	117.99%	125.08%

This table displays calculated financial ratios and metrics derived from Pfizer's official financial filings.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	10/1/2023	12/31/2023	3/31/2024	6/30/2024	9/29/2024	12/31/2024	3/30/2025	6/29/2025	9/28/2025	12/31/2025	3/29/2026
DEI Shares Outstanding	-	-	-	-	-	-	-	-	-	-	5,686,267,431.00
DEI Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-	5,686,267,431.00
DEI Earnings Per Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-	0.47
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-40.41%	-42.03%	-19.51%	2.12%	31.21%	21.92%	-7.82%	10.31%	-5.92%	-1.16%	5.37%
EBITDA Growth	-117.59%	-136.45%	-33.50%	-57.65%	461.10%	172.39%	-14.64%	186.97%	-22.79%	-97.53%	8.65%
EBIT Growth	-137.24%	-178.99%	-45.41%	-104.58%	240.69%	99.73%	-18.61%	3,026.92%	-29.30%	-14,836.36%	13.86%
NOPAT Growth	-125.84%	-160.08%	-35.31%	-68.97%	312.32%	154.73%	6.43%	413.85%	-12.99%	22.37%	-13.68%
Net Income Growth	-127.55%	-167.16%	-43.79%	-97.95%	288.26%	112.44%	-4.80%	6,000.00%	-20.63%	-492.11%	-9.32%
EPS Growth	-127.81%	-168.60%	-43.30%	-97.56%	285.71%	111.86%	-5.45%	5,000.00%	-20.51%	-514.29%	-9.62%
Operating Cash Flow Growth	-42.15%	-38.94%	-10.07%	-47.43%	94.27%	28.26%	114.22%	67.32%	-31.44%	-20.43%	11.99%
Free Cash Flow Firm Growth	-252.76%	-64.40%	-45.49%	-24.52%	-42.30%	110.78%	128.19%	121.56%	118.36%	-192.46%	-136.07%
Invested Capital Growth	25.17%	40.78%	35.29%	32.17%	36.30%	-2.15%	-3.71%	-2.59%	-1.33%	4.69%	5.05%
Revenue Q/Q Growth	3.72%	7.99%	8.05%	-10.73%	33.27%	0.34%	-22.79%	6.84%	13.66%	5.42%	-17.69%
EBITDA Q/Q Growth	-146.64%	-37.22%	309.67%	-68.46%	297.73%	-72.49%	147.36%	6.04%	7.00%	-99.12%	10,772.73%
EBIT Q/Q Growth	-247.73%	-23.18%	182.86%	-103.04%	4,634.62%	-100.23%	25,418.18%	9.30%	9.53%	-149.28%	293.00%
NOPAT Q/Q Growth	-198.10%	-35.23%	205.35%	-81.28%	571.26%	-65.14%	142.97%	-9.62%	13.66%	-50.97%	71.39%
Net Income Q/Q Growth	-201.63%	-41.41%	192.95%	-98.46%	9,218.75%	-90.66%	611.24%	-1.51%	21.24%	-146.17%	264.49%
EPS Q/Q Growth	-202.44%	-40.48%	193.22%	-98.18%	7,700.00%	-91.03%	642.86%	-1.92%	21.57%	-146.77%	262.07%
Operating Cash Flow Q/Q Growth	386.09%	51.62%	-79.20%	-263.39%	476.98%	0.10%	-65.26%	-124.93%	890.89%	16.19%	-51.10%
Free Cash Flow Firm Q/Q Growth	15.87%	-85.26%	24.33%	-4.20%	3.85%	114.04%	100.46%	-20.29%	-18.14%	-170.69%	21.80%
Invested Capital Q/Q Growth	-4.41%	32.34%	2.26%	2.16%	-1.42%	-4.99%	0.63%	3.35%	-0.14%	0.81%	0.98%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	31.29%	48.10%	77.29%	75.16%	70.27%	66.73%	79.26%	74.22%	74.95%	69.97%	75.45%
EBITDA Margin	-13.28%	-16.88%	34.67%	12.25%	36.56%	10.02%	32.10%	31.86%	30.00%	0.25%	33.11%
Operating Margin	-23.50%	-29.43%	27.57%	7.55%	28.01%	13.21%	27.25%	25.82%	23.12%	16.36%	27.90%
EBIT Margin	-24.85%	-28.34%	23.00%	-0.78%	26.64%	-0.06%	20.31%	20.77%	20.02%	-9.36%	21.94%
Profit (Net Income) Margin	-17.61%	-23.06%	20.99%	0.36%	25.27%	2.35%	21.68%	19.98%	21.32%	-9.34%	18.66%
Tax Burden Percent	70.88%	81.38%	91.29%	-46.60%	94.87%	-4,180.00%	106.75%	96.19%	106.48%	99.76%	85.05%
Interest Burden Percent	100.00%	100.00%	99.97%	99.04%	99.98%	90.91%	100.00%	100.00%	100.00%	100.00%	99.97%
Effective Tax Rate	0.00%	0.00%	8.56%	0.00%	4.96%	0.00%	-6.79%	4.63%	-6.48%	0.00%	14.54%
Return on Invested Capital (ROIC)	-12.38%	-10.59%	11.48%	2.35%	13.07%	4.39%	13.37%	11.25%	11.15%	5.28%	11.04%
ROIC Less NNEP Spread (ROIC-NNEP)	-7.09%	-12.13%	8.82%	0.21%	12.15%	1.68%	11.07%	9.92%	9.95%	-2.31%	9.42%
Return on Net Nonoperating Assets (RNNOA)	0.22%	-3.05%	2.15%	0.07%	3.34%	0.85%	5.37%	5.74%	4.91%	-1.27%	4.81%
Return on Equity (ROE)	-12.16%	-13.64%	13.63%	2.42%	16.41%	5.24%	18.74%	16.99%	16.06%	4.01%	15.85%
Cash Return on Invested Capital (CROIC)	-11.46%	-31.60%	-31.29%	-29.63%	-26.42%	11.46%	13.25%	13.48%	11.98%	6.28%	5.19%
Operating Return on Assets (OROA)	-8.39%	-7.97%	6.06%	-0.20%	7.28%	-0.02%	5.91%	6.28%	5.87%	-2.78%	6.69%
Return on Assets (ROA)	-5.95%	-6.48%	5.53%	0.09%	6.91%	0.68%	6.31%	6.04%	6.25%	-2.77%	5.68%
Return on Common Equity (ROCE)	-12.12%	-13.60%	13.59%	2.41%	16.36%	5.23%	18.68%	16.94%	16.01%	4.00%	15.80%
Return on Equity Simple (ROE_SIMPLE)	10.85%	0.00%	-0.30%	-2.92%	4.64%	0.00%	8.76%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-2,220	-3,002	3,751	702	4,713	1,643	3,992	3,608	4,100	2,010	3,446
NOPAT Margin	-16.45%	-20.60%	25.21%	5.29%	26.62%	9.25%	29.10%	24.62%	24.62%	11.45%	23.84%
Net Nonoperating Expense Percent (NNEP)	-5.28%	1.54%	2.66%	2.13%	0.92%	2.71%	2.29%	1.33%	1.20%	7.59%	1.62%
Return On Investment Capital (ROIC_SIMPLE)	-	-1.86%	-	-	-	1.07%	2.61%	2.39%	2.65%	1.33%	2.23%
Cost of Revenue to Revenue	68.71%	51.90%	22.71%	24.84%	29.73%	33.27%	20.74%	25.78%	25.05%	30.03%	24.55%
SG&A Expenses to Revenue	24.32%	31.40%	23.49%	27.98%	18.33%	24.06%	22.10%	23.31%	19.13%	23.71%	20.49%
R&D to Revenue	20.59%	19.82%	16.76%	20.34%	14.75%	17.59%	16.13%	16.95%	23.63%	19.47%	18.18%
Operating Expenses to Revenue	54.80%	77.53%	49.72%	67.61%	42.26%	53.52%	52.00%	48.40%	51.83%	53.61%	47.55%
Earnings before Interest and Taxes (EBIT)	-3,352	-4,129	3,422	-104	4,716	-11	2,785	3,044	3,334	-1,643	3,171
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-1,792	-2,459	5,158	1,627	6,471	1,780	4,403	4,669	4,996	44	4,784
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.82	1.69	1.65	1.78	1.79	1.68	1.58	1.52	1.46	1.61	1.71
Price to Tangible Book Value (P/TBV)	34.12	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	2.55	2.53	2.77	2.83	2.78	2.32	2.29	2.12	2.15	2.23	2.43
Price to Earnings (P/E)	16.87	71.12	0.00	0.00	38.77	18.42	18.12	12.57	13.75	17.92	20.53
Dividend Yield	5.20%	6.14%	6.12%	6.02%	5.74%	6.44%	6.70%	7.15%	7.20%	7.02%	6.36%
Earnings Yield	5.93%	1.41%	0.00%	0.00%	2.58%	5.43%	5.52%	7.95%	7.28%	5.58%	4.87%
Enterprise Value to Invested Capital (EV/IC)	1.78	1.44	1.43	1.47	1.52	1.43	1.39	1.32	1.31	1.36	1.45
Enterprise Value to Revenue (EV/Rev)	2.63	3.27	3.62	3.77	3.57	2.98	2.98	2.85	2.87	3.02	3.22
Enterprise Value to EBITDA (EV/EBITDA)	11.01	26.52	41.80	82.01	19.64	12.63	13.02	10.50	11.36	13.40	14.06
Enterprise Value to EBIT (EV/EBIT)	17.51	184.30	0.00	0.00	54.32	23.66	25.18	17.27	19.67	25.15	25.78
Enterprise Value to NOPAT (EV/NOPAT)	18.17	74.16	0.00	0.00	40.75	15.24	14.44	12.00	12.21	12.82	14.74
Enterprise Value to Operating Cash Flow (EV/OCF)	15.14	22.39	23.14	25.96	18.83	14.90	13.29	11.98	13.76	16.16	17.01
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	12.35	10.32	9.66	10.84	22.18	28.74
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.65	0.81	0.75	0.79	0.73	0.73	0.69	0.69	0.66	0.75	0.71
Long-Term Debt to Equity	0.63	0.69	0.66	0.65	0.63	0.65	0.64	0.65	0.62	0.71	0.67
Financial Leverage	-0.03	0.25	0.24	0.33	0.27	0.51	0.48	0.58	0.49	0.55	0.51
Leverage Ratio	2.16	2.29	2.15	2.33	2.29	2.47	2.34	2.39	2.31	2.41	2.30
Compound Leverage Factor	2.16	2.29	2.15	2.31	2.29	2.25	2.34	2.39	2.31	2.41	2.30
Debt to Total Capital	39.55%	44.60%	42.90%	44.12%	42.24%	42.10%	40.66%	40.98%	39.86%	42.75%	41.62%
Short-Term Debt to Total Capital	1.58%	6.42%	5.08%	7.59%	6.05%	4.54%	2.93%	2.85%	2.78%	2.08%	2.51%
Long-Term Debt to Total Capital	37.97%	38.18%	37.82%	36.53%	36.19%	37.56%	37.74%	38.13%	37.08%	40.67%	39.11%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.17%	0.17%	0.17%	0.17%	0.17%	0.19%	0.20%	0.21%	0.19%	0.20%	0.20%
Common Equity to Total Capital	60.28%	55.23%	56.93%	55.71%	57.58%	57.71%	59.14%	58.81%	59.95%	57.05%	58.18%
Debt to EBITDA	3.84	9.78	14.64	27.41	6.27	4.28	4.35	3.57	3.89	4.59	4.45
Net Debt to EBITDA	0.31	5.97	9.69	20.21	4.35	2.77	3.00	2.68	2.81	3.51	3.43
Long-Term Debt to EBITDA	3.69	8.38	12.91	22.69	5.37	3.82	4.04	3.32	3.62	4.37	4.18
Debt to NOPAT	6.34	27.37	-44.75	-29.09	13.01	5.17	4.82	4.08	4.19	4.39	4.66
Net Debt to NOPAT	0.52	16.69	-29.60	-21.44	9.03	3.34	3.32	3.06	3.02	3.36	3.60
Long-Term Debt to NOPAT	6.08	23.43	-39.45	-24.08	11.14	4.61	4.48	3.79	3.89	4.18	4.38
Altman Z-Score	2.23	1.57	1.79	1.71	1.89	1.82	1.93	1.89	1.93	1.77	1.98
Noncontrolling Interest Sharing Ratio	0.28%	0.29%	0.28%	0.29%	0.29%	0.32%	0.31%	0.33%	0.31%	0.34%	0.33%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.38	0.91	1.05	0.86	1.00	1.17	1.26	1.16	1.28	1.16	1.25
Quick Ratio	1.78	0.51	0.57	0.42	0.56	0.74	0.80	0.67	0.80	0.69	0.75
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-22,805	-42,248	-32,392	-33,752	-32,451	4,555	9,131	7,278	5,957	-4,212	-3,293
Operating Cash Flow to CapEx	426.67%	501.92%	154.83%	-279.59%	1,031.34%	732.93%	414.01%	-94.17%	764.62%	632.90%	599.77%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.34	0.28	0.26	0.25	0.27	0.29	0.29	0.30	0.29	0.30	0.30
Accounts Receivable Turnover	5.10	5.29	4.71	5.10	4.65	5.53	5.47	5.44	4.37	5.36	5.18
Inventory Turnover	2.74	2.60	2.30	2.16	1.78	1.70	1.59	1.54	1.44	1.49	1.56
Fixed Asset Turnover	4.16	3.38	3.06	3.03	3.26	3.41	3.36	3.38	3.36	3.32	3.35
Accounts Payable Turnover	4.66	3.69	4.00	4.20	3.66	2.89	3.20	3.46	3.23	2.96	3.44
Days Sales Outstanding (DSO)	71.56	69.01	77.45	71.54	78.49	66.05	66.71	67.10	83.46	68.06	70.42
Days Inventory Outstanding (DIO)	133.07	140.20	159.04	168.89	205.15	215.10	229.16	237.07	253.35	244.27	234.18
Days Payable Outstanding (DPO)	78.32	98.87	91.18	86.84	99.67	126.19	114.15	105.35	112.95	123.50	106.06
Cash Conversion Cycle (CCC)	126.31	110.33	145.31	153.59	183.97	154.97	181.72	198.83	223.86	188.82	198.54
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	102,382	135,492	138,557	141,555	139,546	132,580	133,418	137,885	137,689	138,802	140,157
Invested Capital Turnover	0.75	0.51	0.46	0.44	0.49	0.47	0.46	0.46	0.45	0.46	0.46
Increase / (Decrease) in Invested Capital	20,585	39,246	36,143	34,454	37,164	-2,912	-5,139	-3,670	-1,857	6,222	6,739
Enterprise Value (EV)	182,291	194,808	198,486	207,822	212,103	189,841	185,952	181,941	179,975	189,119	203,814
Market Capitalization	176,845	150,704	152,212	156,345	164,844	147,900	142,874	135,196	135,089	139,242	153,757
Book Value per Share	$17.17	$15.76	$16.31	$15.48	$16.29	$15.56	$15.94	$15.60	$16.32	$15.21	$15.85
Tangible Book Value per Share	$0.92	($7.73)	($7.04)	($7.41)	($6.40)	($6.31)	($5.66)	($5.81)	($4.86)	($6.77)	($5.96)
Total Capital	160,800	161,176	162,097	157,425	160,259	152,848	152,746	150,809	154,808	151,570	154,859
Total Debt	63,596	71,888	69,539	69,450	67,701	64,351	62,109	61,797	61,712	64,795	64,455
Total Long-Term Debt	61,048	61,538	61,307	57,506	58,002	57,405	57,639	57,502	57,409	61,641	60,565
Net Debt	5,176	43,830	45,998	51,202	46,987	41,647	42,779	46,428	44,591	49,578	49,754
Capital Expenditures (CapEx)	810	1,044	704	637	651	917	564	618	602	845	436
Debt-free, Cash-free Net Working Capital (DFCFNWC)	1,243	-6,801	-1,778	-1,150	-241	-6,168	-3,438	-2,977	-353	-4,528	-711
Debt-free Net Working Capital (DFNWC)	45,424	5,889	10,150	5,950	9,711	14,309	13,879	10,272	14,631	9,068	12,364
Net Working Capital (NWC)	42,876	-4,461	1,918	-5,994	12	7,363	9,409	5,977	10,328	5,914	8,474
Net Nonoperating Expense (NNE)	156	358	628	654	240	1,225	1,019	680	550	3,649	750
Net Nonoperating Obligations (NNO)	5,178	46,204	45,999	53,580	46,988	44,083	42,781	48,873	44,593	52,027	49,753
Total Depreciation and Amortization (D&A)	1,560	1,670	1,736	1,731	1,755	1,791	1,618	1,625	1,662	1,687	1,613
Debt-free, Cash-free Net Working Capital to Revenue	1.79%	-11.42%	-3.24%	-2.08%	-0.41%	-9.69%	-5.50%	-4.66%	-0.56%	-7.24%	-1.12%
Debt-free Net Working Capital to Revenue	65.57%	9.89%	18.49%	10.79%	16.36%	22.49%	22.22%	16.09%	23.30%	14.49%	19.53%
Net Working Capital to Revenue	61.89%	-7.49%	3.49%	-10.87%	0.02%	11.57%	15.06%	9.36%	16.45%	9.45%	13.38%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.42)	($0.59)	$0.55	$0.01	$0.79	$0.07	$0.52	$0.51	$0.62	($0.28)	$0.47
Adjusted Weighted Average Basic Shares Outstanding	5.65B	5.64B	5.66B	5.67B	5.67B	5.66B	5.68B	5.69B	5.69B	5.68B	5.69B
Adjusted Diluted Earnings per Share	($0.42)	($0.59)	$0.55	$0.01	$0.78	$0.07	$0.52	$0.51	$0.62	($0.29)	$0.47
Adjusted Weighted Average Diluted Shares Outstanding	5.65B	5.71B	5.70B	5.70B	5.71B	5.70B	5.71B	5.71B	5.71B	5.71B	5.73B
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	5.65B	5.65B	5.67B	5.67B	5.67B	5.67B	5.69B	5.69B	5.69B	5.69B	5.70B
Normalized Net Operating Profit after Tax (NOPAT)	-2,111	-1,206	3,844	1,580	5,010	2,168	3,091	3,591	2,896	2,433	3,531
Normalized NOPAT Margin	-15.65%	-8.28%	25.83%	11.89%	28.30%	12.20%	22.54%	24.50%	17.39%	13.86%	24.44%
Pre Tax Income Margin	-24.85%	-28.34%	22.99%	-0.78%	26.64%	-0.06%	20.31%	20.77%	20.02%	-9.36%	21.94%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	87.23%	428.50%	-3,387.64%	-365.73%	220.52%	117.99%	121.04%	89.34%	98.35%	125.08%	129.78%
Augmented Payout Ratio	87.23%	428.50%	-3,387.64%	-365.73%	220.52%	117.99%	121.04%	89.34%	98.35%	125.08%	129.78%

Financials Breakdown Chart

Key Financial Trends

Pfizer (NYSE:PFE) delivered a solid top-line and cash-flow story in Q4 2025, with a strong gross margin and healthy operating cash flow, backed by a sizable balance sheet. However, the quarter also included a meaningful net loss driven by large non-operating expense, underscoring earnings volatility on a quarterly basis. Below are the most notable themes based on four years of quarterly data.

Strong gross margin in Q4 2025: Total Revenue about $17.56B with Gross Profit about $12.29B, roughly a 70% gross margin.
Robust operating cash flow: Net cash from continuing operating activities in Q4 2025 was about $5.35B, up from earlier quarters and signaling solid cash generation from core operations.
Financing flexibility through debt issuance: Net cash from financing activities was about $0.60B in Q4 2025, supported by debt issuance of about $6.09B (offset by repayments and dividends), indicating access to capital markets when needed.
Modest capital spending relative to cash flow: Purchase of Property, Plant & Equipment was about $0.85B in Q4 2025, suggesting capex discipline while still investing in assets.
Steady shareholder returns via dividends: Pfizer has maintained quarterly dividends around $0.86 per share in recent quarters, reflecting a consistent return to shareholders.
Strong liquidity backdrop on the balance sheet: Across recent quarters, cash and short-term investments remained substantial (Q3 2025 snapshot shows roughly $15B in cash/equivalents plus investments), with total assets around $209B, supporting liquidity and flexibility.
Investments in R&D and SG&A remain ongoing: R&D expense around $3.42B and SG&A expense around $4.16B in Q4 2025, totaling about $7.58B—consistent with a pipeline-focused, growth-oriented company.
Debt levels and leverage remain high but manageable: Long-term debt around $57.4B and total liabilities near $115.6B at the latest balance sheet; this level is typical for large pharma and supports ongoing financing needs.
Quarterly net income declined in Q4 2025: Net income attributable to common shareholders was about -$1.65B, highlighting a quarterly earnings swing.
Large non-operating expense pressure in Q4 2025: Other income/expense, net was about -$4.515B, a substantial drag on pretax income and net results for the quarter.

05/18/26 01:49 AM ETAI Generated. May Contain Errors.

Pfizer Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Pfizer's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

The last 5 years of Pfizer's net income performance:

2021: $22.03 billion
2022: $31.41 billion
2023: $2.16 billion
2024: $8.06 billion
2025: $7.81 billion

Find out what analysts predict for Pfizer in the coming months.

Pfizer's total operating income in 2025 was $14.24 billion, based on the following breakdown:

Total Gross Profit: $46.51 billion
Total Operating Expenses: $32.27 billion

Over the last 10 years, Pfizer's total revenue changed from $48.85 billion in 2015 to $62.58 billion in 2025, a change of 28.1%.

Pfizer's total liabilities were at $121.39 billion at the end of 2025, a 2.8% decrease from 2024, and a 60.8% increase since 2015.

In the past 10 years, Pfizer's cash and equivalents has ranged from $416 million in 2022 to $3.64 billion in 2015, and is currently $1.14 billion as of their latest financial filing in 2025.

Over the last 10 years, Pfizer's book value per share changed from 10.48 in 2015 to 15.21 in 2025, a change of 45.1%.

Related Companies

Financial statements for NYSE:PFE last updated on 5/8/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pfizer (PFE) Financials

Financials Breakdown Chart

Key Financial Trends

Pfizer Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Pfizer (PFE) Financials

Annual Income Statements for Pfizer

Quarterly Income Statements for Pfizer

Annual Cash Flow Statements for Pfizer

Quarterly Cash Flow Statements for Pfizer

Annual Balance Sheets for Pfizer

Quarterly Balance Sheets for Pfizer

Annual Metrics And Ratios for Pfizer

Quarterly Metrics And Ratios for Pfizer

Financials Breakdown Chart

Key Financial Trends

Pfizer Financials - Frequently Asked Questions

When does Pfizer's financial year end?

How has Pfizer's net income changed over the last 10 years?

What is Pfizer's operating income?

How has Pfizer's revenue changed over the last 10 years?

How much debt does Pfizer have?

How much cash does Pfizer have?

How has Pfizer's book value per share changed over the last 10 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools